This, coupled with the fact that the actions of GALP were not fully inhibited by guanethidine, suggests that further studies are required to elucidate how GALP exerts its anti-obesity effects. The gene discussed is GALP; the disease is obesity due to melanocortin 4 receptor deficiency.